Navigation Links
Sanofi-aventis Announces Second Quarter 2009 Results
Date:7/29/2009

Research and development expenses rose by 1.6% to euro 1,108 million. At constant exchange rates, they were down by 2.5%, reflecting selectivity in R&D projects and cost savings.

Selling and general expenses increased by 5.9%, or 1.5% at constant exchange rates, to euro 1,895 million. The ratio of selling and general expenses to net sales fell by 1.2 points to 25.5%, reflecting the ongoing program of adaptation to market conditions.

Other current operating income, net of expenses totaled euro 132 million, compared with euro 74 million for the second quarter of 2008. The year-on-year change in this line reflects gains on currency hedging and an increase in the royalty collected by sanofi-aventis on sales of Copaxone((R)) in North America.

Operating income - current was up 26.8% at euro 3,046 million. At constant exchange rates, growth was 16.0%. The ratio of operating income - current to net sales improved by 5.1 points to 41.0%.

Net financial expenses were virtually unchanged at euro 70 million. Financial expenses rose slightly, reflecting the change in net debt arising from payment of the Zentiva purchase consideration at the end of the first quarter and from the dividend payout.

The effective tax rate was 0.6 of a point lower at 29%, in line with the 2008 full-year rate.

The share of profits from associates was up 22.6% at euro 266 million, with the share of after-tax profits from territories managed by BMS under the Plavix((R)) and Avapro((R)) alliance 42.7% higher at euro 207 million due to a good performance by Plavix((R)) in the United States and a favorable dollar effect. The contribution from Merial rose by 21.6%, and the contribution from Sanofi Pasteur MSD also grew.

Minority interests were 5.7% higher at euro 111 million. The share of pre-tax profits paid to BM
'/>"/>

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... BEIJING , July 24, 2015 Origin Agritech ... supplier of crop seeds in China , ... third quarter fiscal year 2015 ended June 30, 2015, before ... The Company will host a teleconference on August 5th, 2015, ... time to discuss the results. To participate in ...
(Date:7/24/2015)... 2015 , Adds integrated small ... product offering for chronic kidney disease and oncology patients ... complications and dermatology , Increases group revenue and ... ,the Company"), a leading China -based ... biopharmaceutical products, today announced that it has acquired the ...
(Date:7/23/2015)... LOS ANGELES , July 23, 2015 ImmunoCellular ... plans to report financial results for the second quarter 2015 ... hold a conference call and webcast on that day at ... results and provide a business update. The call will be ...   , , , LIVE CALL: ...
(Date:7/23/2015)... , ... July 23, 2015 , ... Science and technology ... to new drug therapies and devices – according to Susan Chang, MD, director of ... session on how science and new technology are impacting the development of new treatments ...
Breaking Biology Technology:Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 33SBio Acquires Zhejiang Wansheng Pharmaceutical 23SBio Acquires Zhejiang Wansheng Pharmaceutical 33SBio Acquires Zhejiang Wansheng Pharmaceutical 4ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015 2Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 2Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 3
... fast and easy detection of mycoplasma,contamination , ... Staggs ,Genetic Applications LLC , Heinz Miller ,Stratagene , ... potency of transfection reagents. 1 Cells must be ... ,transfection reagent and ...
... using LipoTAXI transfection reagent , Peter ... Karmiol ,Clonetics Corporation, Walkersville, Maryland , LipoTAXI ... that offers,low cellular toxicity and high transfection ... is described for optimizing the amounts of ...
... transfection reagent: A proven choice , ... transfection reagent offers,improved, ... growing in,suspension. In this article, we summarize the ... LipoTAXI reagent. Optimizing transfection,conditions is a critical, preliminary ...
Cached Biology Technology:Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection,of Mammalian Cells 2Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection,of Mammalian Cells 3Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 2Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 3Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 4Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells 5Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 2Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 3Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 4Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 5Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 6Versatile Transfection Reagent Offers Low Toxicity and Consistent,Performance 7
(Date:7/21/2015)... Sweden , July 21, 2015 Today, ... FPC1025. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
(Date:7/13/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD AND SYSTEM. ... secure method to make payments.  With this patent, ... with its groundbreaking voice-direct payment patent application, with ...
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... natural selection favours traits that enhance dispersal of ... this theory, however, is relatively scarce. A study ... Biological and Environmental Sciences of the University of ... evolution of traits facilitating dispersal in an outer ...
... much iron is toxic, and can cause fatal organ failure. ... also be maintained. In a study published today in ... (EMBL) in Heidelberg, Germany, have discovered that a group of ... and as such are essential for cell survival. More specifically, ...
... ANN ARBOR, Mich.---In one of the first human studies ... the controversial chemical Bisphenol A, or BPA, may be related ... the researchers are quick to point out that these results ... documented adverse effects of BPA on semen in rodents, but ...
Cached Biology News:UH: Insular evolution: Large and big-footed voles in an outer archipelago 2Supply and demand 2Sperm may be harmed by exposure to BPA, study suggests 2